Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO) (HW794036)

Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)
Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)
価格(USD):
スペック:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号HW794036
説明
Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO) (HW794036) is a human monoclonal antibody detecting Flt-3/Flk-2. Expressed in Mammalian cells.
種反応性Human
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Human
クローン性Monoclonal
アイソタイプIgG
クローンIDIMC-EB10
生物学的活性 IMC-EB10 (10 ug/mL, 1 h) reduces FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK in Hb1119 and SEM-K2 cells, but activates them in REH and RS411 cells [1]. IMC-EB10 (10 ug/mL, 1 h) activates FLT3 and downstream Akt in ALLs [1]. IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of wild-type FLT3 and ligand-independent constitutive phosphorylation of ITD-mutant FLT3 in EOL-1, EM3, BaF3-ITD and MV4;11 cells [4]. IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of MAPK, AKT and Stat5 in EOL-1, EM3, BaF3-ITD and MV4;11 cells [4]. IMC-EB10 (1.5-100 nM, 1 h) inhibits proliferation of FLT3-Fc-induced proliferation of EOL-1 and BaF3-ITD cells [4]. Western Blot Analysis [1] Cell Line: Hb1119, SEM-K2 cells Concentration: 10 ug/mL Incubation Time: 1 h Result: Reduced FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK. Western Blot Analysis [1] Cell Line: REH, RS411 cells Concentration: 10 ug/mL Incubation Time: 1 h Result: Activated FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK. Western Blot Analysis [1] Cell Line: ALLs Concentration: 10 ug/mL Incubation Time: 1 h Result: Activated FLT3 and downstream Akt. . Blocked the phosphorylation and constitutive phosphorylation of MAPK, inhibited FL-induced phosphorylation of AKT and Stat5 phosphorylation in EOL-1 and BaF3-ITD cells. Parmacokinetics Species Dose Route T 1/2 AUC 0-inf Mice [2] 20 mg/kg i.p. 96 h 38327 ug·h/mL IMC-EB10 (400 ug/10 mg/kg, i.p.
発現システム Mammalian cells
ターゲット FLT3, Stem cell tyrosine kinase 1, Fetal liver kinase-2, STK-1, STK1, FLK2, CD135, Receptor-type tyrosine-protein kinase FLT3, Fms-like tyrosine kinase 3, FL cytokine receptor, FLK-2, FLT-3
エンドトキシンレベル < 10 EU/mg
純度 >95% purity as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 P36888
形態 Liquid
保存バッファー 0.01M PBS pH 7.4

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名IMC-EB10
背景

Receptor-type tyrosine-protein kinase FLT3 (CD135) is a ~112 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B.

参考文献 1. Piloto O, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51 [HW794036]
2. Erik Corcoran, et al. Abstract #2923: Preclinical pharmacokinetic and pharmacodynamic evaluation of the anti-FLT3 monoclonal antibody IMC-EB10. Cancer Res 1 May 2009; 69 (9_Supplement): 2923. [HW794036]
3. David Surguladze, et al. Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody.IMC-EB10 and Methotrexate,Blood,Volume 112, Issue 11,2008,Page 3964,ISSN 0006-4971, [HW794036]
4. Li Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood.2004 Aug 15;104(4):1137-44. View More [HW794036]
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD135/FLT3 (IMC-EB10)

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト